Across TCGA pan-cancer cohorts, KLF2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated KLF2 data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher KLF2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KLF2 expression acts as an unfavorable survival marker.
DLBC and UCEC are the cancer types where KLF2 Mutation most reproducibly stratifies survival.